Skip to main content

Table 2 Multivariate analysis of prognostic factors for survival in overweight and obese patient with ES-SCLC

From: Carboplatin versus cisplatin in combination with etoposide in the first-line treatment of small cell lung cancer: a pooled analysis

Characteristics

Progression-free survival

Overall survival

HR

95%CI

p value

HR

95%CI

p value

Age

1.00

0.99 - 1.01

0.6869

1.01

1.00 - 1.02

0.1479

Gender

0.86

0.71 - 1.04

0.1270

0.68

0.55 - 0.85

0.0005

BMI

0.99

0.97 - 1.01

0.4396

0.97

0.95 - 1.00

0.0386

ECOG

0.92

0.79 - 1.06

0.2268

1.39

1.20 - 1.62

< 0.0001

EP regimen

0.76

0.63 - 0.92

0.0041

0.79

0.64 - 0.97

0.0220

  1. Abbreviations: HR hazard ratio, CI confidence interval, ECOG Eastern Cooperative Oncology Group, PS performance status, BMI body mass index, EP etoposide plus cisplatin
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us